Genmab A/S (NASDAQ:GMAB) Shares Sold by Exchange Traded Concepts LLC

Exchange Traded Concepts LLC cut its position in Genmab A/S (NASDAQ:GMAB) by 12.2% during the third quarter, HoldingsChannel.com reports. The fund owned 6,300 shares of the company’s stock after selling 874 shares during the period. Exchange Traded Concepts LLC’s holdings in Genmab A/S were worth $154,000 at the end of the most recent reporting period.

A number of other institutional investors have also recently made changes to their positions in the company. Russell Investments Group Ltd. boosted its stake in Genmab A/S by 137.7% during the first quarter. Russell Investments Group Ltd. now owns 939 shares of the company’s stock worth $28,000 after buying an additional 544 shares during the last quarter. GAMMA Investing LLC boosted its stake in Genmab A/S by 194.0% during the first quarter. GAMMA Investing LLC now owns 1,135 shares of the company’s stock worth $34,000 after buying an additional 749 shares during the last quarter. Allspring Global Investments Holdings LLC acquired a new position in Genmab A/S during the first quarter worth $43,000. Headlands Technologies LLC boosted its stake in Genmab A/S by 1,702.8% during the second quarter. Headlands Technologies LLC now owns 5,138 shares of the company’s stock worth $129,000 after buying an additional 4,853 shares during the last quarter. Finally, Benjamin F. Edwards & Company Inc. boosted its stake in Genmab A/S by 7.1% during the second quarter. Benjamin F. Edwards & Company Inc. now owns 7,227 shares of the company’s stock worth $182,000 after buying an additional 478 shares during the last quarter. 7.07% of the stock is owned by institutional investors and hedge funds.

Genmab A/S Stock Down 0.9 %

Shares of Genmab A/S stock opened at $22.78 on Tuesday. Genmab A/S has a 52 week low of $22.52 and a 52 week high of $32.89. The business’s fifty day simple moving average is $25.66 and its 200-day simple moving average is $27.01. The firm has a market cap of $15.06 billion, a PE ratio of 18.98, a price-to-earnings-growth ratio of 0.71 and a beta of 0.98.

Genmab A/S (NASDAQ:GMAB) last announced its quarterly earnings results on Thursday, August 8th. The company reported $0.22 EPS for the quarter, missing the consensus estimate of $0.29 by ($0.07). The business had revenue of $779.50 million during the quarter, compared to analyst estimates of $734.60 million. Genmab A/S had a net margin of 29.06% and a return on equity of 17.48%. As a group, equities analysts expect that Genmab A/S will post 1.27 earnings per share for the current year.

Wall Street Analyst Weigh In

A number of research firms have weighed in on GMAB. Redburn Atlantic began coverage on Genmab A/S in a research note on Tuesday, October 8th. They set a “buy” rating on the stock. HC Wainwright reissued a “buy” rating and set a $50.00 price objective on shares of Genmab A/S in a research note on Wednesday, October 16th. Royal Bank of Canada raised Genmab A/S from a “sector perform” rating to an “outperform” rating in a research note on Monday, July 15th. BTIG Research boosted their price objective on Genmab A/S from $46.00 to $47.00 and gave the stock a “buy” rating in a research note on Thursday, June 27th. Finally, JPMorgan Chase & Co. reissued a “neutral” rating on shares of Genmab A/S in a research note on Tuesday, August 20th. One research analyst has rated the stock with a sell rating, two have issued a hold rating and nine have given a buy rating to the stock. Based on data from MarketBeat, Genmab A/S has an average rating of “Moderate Buy” and a consensus price target of $45.20.

Genmab A/S Profile

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC.